Anjali Ahn, MD Beth Israel Deaconess Medical Center May 1, 2015
|
|
- Dylan Elliott
- 5 years ago
- Views:
Transcription
1 Anjali Ahn, MD Beth Israel Deaconess Medical Center May 1, 2015
2
3 Ms G. is a 50yo female Boston police officer presents with chief complaint: I ve never been a good sleeper! Where do you start? Let s discuss the components of a good sleep history
4 Chronology of sleep problem Sleep routine Daytime symptoms Comorbid conditions and symptoms Daytime factors
5 Difficulty falling asleep or staying asleep or both? When did it start and what was going on at that time? What was your sleep like before your sleep issues started? What interventions or medications have you tried already to help with your sleep?
6 History of her sleep problems: Ms G. has had sleep onset insomnia for 30 yr. Only DFA, no DMS. She recalls sleeping well when she was in college. In the past, she has tried trazodone (ineffective), lorazepam (groggy/ineffective), clonazepam (groggy/ineffective), doxepin (doesn't recall), propranolol (doesn't recall effect), ambien (did not like). She currently uses sonata 10mg which does not help. Uses 3x per week. Has script for lunesta 1mg which she will use on the alternate nights (also ineffective).
7 What is the range of bedtimes (WD, WE)? What is the range of rise times (WD, WE)? How long does it take to fall asleep? How often do you wake up? Can you get back to sleep? What do you do typically prior to bed? After MNA? Where do you sleep and with whom? How do you feel when you are up in the middle of the night?
8 Sleep Routine: Ms G. takes sleep meds around 9p. Reads and gets in bed around 10p. Continues to read. Does not feel sleepy at this time at all. Will read for most of the night. No clock, tv, computer, phone. Keeps room dark and clean. May not fall asleep until near dawn. OOB 6:30-7am. Rarely OOB 8:30am. She admits that she is very alert or on guard at night and finds it hard to relax and will wake to the slightest noise. She lives alone but has 4 dogs. The dogs sleep in the bedroom with her. She does feel safer having her dogs with her.
9 Sleep Routines (continued): How does she feel at night? Suspect hypervigilance: Her father was physically abusive to her mother and her. She then worked 30 yr on the street as a Boston police officer and only in the last yr, has she taken a office position in the police force. It is a "toxic job" but she still loves it and looks forward to going to work.
10 Are you sleepy during the day? Do you doze unintentionally or nap? Or just tired/fatigued? Very unusual for pure insomniacs to be able to doze/nap. Irritable, mood changes? Does you mood completely improve after a good night s rest? There has to be daytime impairment to make a diagnosis of insomnia.
11 Daytime symptoms: Ms G. is exhausted and tired But she can t doze off and can t nap.
12 Caffeine use? How much and when? Alcohol use? Tobacco or illicits? Physical activity? Daytime structure? These daytime habits along with sleep-wake schedule, prebt routine and sleep environment help defines the term sleep hygeine.
13 Daytime factors Drinks 1 coffee in am, no etoh, no tobacco/illicits Works 9:30a-6:30p and overtime to 8pm twice a wk
14 H/o mood disorders? Early morning awakenings in depression Ruminations/worry in anxious patients Compulsive prebt routines in OCD patients Hypervigilance in PTSD patients Sxs or suspicion of sleep disordered breathing? Snoring, witnessed apnea, nocturia, obesity, morning headaches Sxs of restless leg syndrome? Leg twitching or kicking, urge to move legs, relief with movement, diurnal variation, antidepressant use Sxs of circadian rhythm disturbance? Strong morning or evening preference, preferred sleep schedule on weekends or vacations
15 Comorbid conditions and sxs: History of OSA, on PAP therapy and uses faithfully Checked her compliance in office using PAP 5-6 hr per night Dx of OCD and PTSD
16 Medical conditions Chronic pain syndromes Diabetes (nocturia, neuropathy) BPH Serious cardiopulmonary conditions GERD Menopausal symptoms Medications that can fragment sleep Diuretics > nocturia Beta blocker can cause nightmares, can cause fatigue Many antidepressants suppress REM sleep, result in sleep fragmentation, aggravate RLS or RBD
17 Patient reported complaint of difficulty initiating or maintaining sleep SOL > 30 min or WASO > 30 min 1 Objective measures (PSG/actigraphy) show sig overlap btw insomniacs and good sleepers 2 Many patients with insomnia overestimate SOL and WASO and underestimate sleep duration altered perception 3 Sxs occur despite adequate opportunity Sxs produce a deficit in daytime function Buysse DJ JAMA 2013, 1 Lichstein KL, Behav Res Ther 2003, 2 Rosa RR, Psychosom Med 2000, 3 Edinger JD Sleep Me
18 ICSD-1 & ICSD-2 subtyped primary & secondary (comorbid) Subtyped primary insomnia into psychophysiologic, idiopathic and paradoxical ICSD-3 represents marked departure from this nosology Vast majority of insomnia subtypes share characteristics regardless of whether primary or comorbid Typically all are assoc with maladaptive cognitions and behaviors Treatment approaches are same regardless of subtype or comorbidity Diag reliability and validity have been challenged ICSD-3 elected to consolidate all insomnia subtypes Sateia MJ Chest 2014
19 ICSD-3 general criteria for insomnia diagnosis A report of sleep initiation or maintenance problems Adequate opportunity & circumstances for sleep Daytime consequences Symptoms at least 3x per week ICSD-3 Insomnia Diagnoses Chronic insomnia disorder >3 months duration Short-term insomnia disorder Other insomnia disorder Sateia MJ Chest 2014
20 Slide borrowed from Suzie Bertisch, MD
21 Prevalence ~ 10-20% in the general population Based on predominant symptom (DFA or DMS) Prevalence of sleep maintenance sxs 50-70% Prevalence of sleep onset sxs 35-60% Prevalence of nonrestorative sleep 20-25% Multiple sleep sxs more common Morin CM Can J Psych 2011, McCrae CS Sleep Med Rev 2001, Buysse DJ JAMA 2013
22 Depression, female sex, older age, lower SES, comorbid medical/psych disorders, marital status, and AA race 1 Follows a chronic course in most patients Insomnia is a risk factor for depression 2, metabolic syndrome 3, HTN 4, and CAD 5 1 Ohayon MM Sleep Med Rev 2002, 2 Baglioni C J Affect Disord 2011, 3 Troxel WM Sleep 2010, 4 Vgontzas AN Sleep 2009, 5 Laugsand LE Circulation 2011.
23 Individuals with insomnia focus cognitively or ruminate on insomnia and develop learned sleep preventing assoc. Maladaptive behaviors (prolonged time in bed, daytime napping, increased alcohol use) help to perpetuate Cortical arousal results from conditioning and promotes abnormal sensory and info processing and memory formation AIE pathway Attention, Intention, Effort 2 Basic idea is that normal sleep is largely automatic and involuntary and can be inhibited by selectively directing attention to it Explicit intention to sleep compromises the automaticity Increased effort results in maladaptive behaviors 1 Riemann D Sleep Med Rev 2010, 2 Espie CA Sleep Med Rev 2006
24 Neurocognitive Model of Insomnia 1 Riemann D Sleep Med Rev 2010
25 Insomnia: The Hyperarousal Model Elevated metabolic rate, cortisol, & ACTH during sleep period 1 Higher heart rates in insomnia patients and reduced parasympathetic tone in HR variability 1 Increased high freq EEG activity during NREM sleep 2 Increased activity on neuroimaging during sleep 2 1 Bonnet MH Sleep Med Rev 2010, 2 Riemann D Sleep Med Rev 2010,
26 Careful clinical history Sleep diaries, actigraphy Sleep study testing only if coexisting sleep disorder is suspected 3-P model 2 Predisposing factors Ms G : h/o childhood abuse, fam h/o insomnia Precipitating factors Ms G : when she started work 30 yr ago as a police officer on the street Perpetuating factors Ms G : hypervigilance, PTSD/OCD, increased time in bed 1 Buysse DJ JAMA 2013, 2 Spielman AJ Psych Clin North Am 19
27 Behavioral therapy Pharmacologic therapy
28 Maladaptive thoughts, beliefs and behaviors are often perpetutating factors in chronic insomnia. These are the targets of therapy for CBT. Use of sleep diaries to help inform baseline patterns Requires patient investment in changing patterns of behavior Use of voluntary waking behaviors to influence sleep Indicated for both primary and comorbid insomnia
29
30 Benzodiazepine receptor agonist drugs (BzRA) Benzodiazepines Non-benzodiazepines (zolpidem, zaleplon, eszopiclone) Sedating antidepressants Trazodone, doxepin, mirtazapine Melatonin receptor agonists Ramelteon, melatonin Gabapentin & pregabalin Antihistamines Antipsychotics
31 Facilitates Sleepiness Facilitates Arousal Adenosine X GABA X Galanin X Glycine X Melatonin X Acetylcholine X Dopamine X Glutamate X Histamine X Norepinephrine X Orexin 1 and 2 X Serotonin X GABA = γ-aminobutyric acid Gulyani S Chest 2012
32 Common OTC Sleep Aids Mechanism of Action FDA Indication (Insomnia) Nytol H1 receptor antagonist Yes Common Side Effects Daytime drowsiness/grogginess, daytime impairment, dizziness, dyskinesia, xerostomia, urinary retention Half-life 4-8 h Sominex H1 receptor antagonist Yes Same as Nytol 4-8 h Sleepinal H1 receptor antagonist Yes Same as Nytol 4-8 h Unisom H1 and H2 receptor antagonist Yes Daytime grogginess effect, daytime impairment 6-8 h Melatonin MT 1 and MT 2 receptor agonist No Daytime grogginess effect, daytime impairment, confusion min Tryptophan Modulation of serotonin No Combination drugs Diphenhydramine H1 and H2 receptor antagonist No Drowsiness, headaches, dizziness Daytime drowsiness, daytime impairment 1-3 h N/A b Tylenol PM H1 receptor antagonist No Same as Nytol N/A b Anacin PM H1 receptor antagonist No Same as Nytol N/A b Nyquil Herbal aids Valerian, kava, chamomile H1 and H2 receptor antagonist No Daytime grogginess N/A b Unknown No Hepatotoxicity N/A b Adapted from Gulyani S Chest 2012
33 FDA Approved Drugs for Insomnia Trade Name Generic Name Mechanism of Action Dose, mg Common Side Effects Half-life, h ProSom Estazolam GABA A modulator 1-2 Dalmane Flurazepam GABA A modulator Halcion Triazolam GABA A modulator Restoril Temazepam GABA A modulator Doral Quazepam GABA A modulator Daytime grogginess effect, dry mouth, weakness, coordination issues, dizziness GI upset, irritability drug dependence, ataxia, dizziness, headache Amnestic events, euphoria, GI upset, headache, dizziness, tingling of skin, coordination issues Daytime grogginess effect, GI upset, dizziness, hypotension, blurred vision GI upset, hallucinations, slurred speech, dizziness, headache a Sonata Lunesta Ambien Rozerem Zaleplon Eszopiclone Zolpidem Ramelteon GABA A α1βγ2 modulator GABA A α1-3βγ2 modulator GABA A α1βγ2 modulator Melatonin (MT 1 and MT 2 receptor agonist) b Silenor Doxepin H1 receptor antagonist Dizziness, loss of appetite, eye pain, coordination issues, numbness, headache Disorders of taste, respiratory effects, dizziness, headache, GI upset, coordination issues Headache, dizziness, amnestic events, confusion, slurred speech Fatigue, dizziness, nausea, GI upset, fertility issues 1-3 Urinary retention, respiratory effects, dizziness 15 Adapted from Gulyani S Chest
34 Non-FDA-Approved Antidepressant Meds Used as Sleep Aids Class Generic Trade Name Dose, mg Side Effects Half-life, h Tricyclic antidepressants Trazodone Desyrel Nervousness, fatigue, diarrhea 7 Amitriptyline Elavil 75 Weight gain, xerostomia 15 Nortriptyline Pamelor 25 Dysrhythmia, cardiotoxicity H1 receptor antagonist Mirtazapine Remeron 15 Weight gain, increase of appetite, liver toxicity SNRI, 5-HT2 antagonist Nefazodone Serzone 100 Headaches, dizziness, confusion 2-4 D2 and 5-HT2 receptor antagonist Quetiapine Seroquel Agitation, dizziness, extrapyramidal effects 6 5-HT =5-hydroxytryptamine (serotonin); D2 =dopamine; SNRI =serotonin-norepinephrine reuptake inhibitor. Adapted from Gulyani S Chest 2
35 The five subunits of a GABA A receptor. In addition to a Cl channel pore and two GABA active binding sites, a BZD allosteric binding site exists at the interface of the γ2 subunit and one of four isoforms of the α subunit (α1, α2, α3, and α5). BZDs have nonselective binding affinity for the BZD site regardless of the α-subunit isoform, whereas newer BZD receptor agonist insomnia medications have more selective affinity to the BZD binding sites that contain specific α-subunit isoforms as depicted in the key. This selectivity allows for not only greater control of clinical effects but also association with specific side effect profiles (Table 4). BZD = benzodiazepine; Cl = chloride ion; GABA = γ-aminobutyric acid.
36 Effects Mediated by GABA A Receptor α Subunits Clinically Relevant Effects Side Effects Subunit Sedation Anxiolytic Muscle Relaxant Anticonvulsive Antidepressant Amnesia Dependence α1 X X X X α2 X X X α3 X α5 X Zolpidem (Ambien): α1 Zaleplon (Sonata): α1 Eszopiclone (Lunesta) : α2 & α3
37 Edited from Table 3 in Buysse DJ JAMA 2013 Class/Drug Benzodiazepine TMax (hours) Elimination Half Life (hours) Usual Hypnotic Dose (mg) Triazolam Yes Temazepam Yes Estazolam Yes Approved for Insomnia Comments Early reports of adverse effects were likely dose-related Metabolized mainly by conjugation (no CYP-related drug interactions) Triazolo ring structure similar totriazolam Quazepam Yes Active metabolite accumulates with repeated dosing Flurazepam Yes Active metabolite accumulates with repeated dosing Alprazolam No Lorazepam No Often noted for significant withdrawal Metabolized by conjugation (no CYP-related drug interactions) Clonazepam No Often used for other sleep disorders including RLS, parasomnias
38 Edited from Table 3 in Buysse DJ JAMA 2013 Class/Drugs Non-Benzodiazepine TMax (hours) Elimination Half Life (hours) Usual Hypnotic Dose (mg) Approved for Insomnia Comments Zaleplon 1 (0.5 2) 1 ( ) 5 20 Yes Shortest-acting BzRA Eszopiclone 1.5 (0.5 2) 6 (5 8) 1 3 Yes ~30% may have unpleasant taste or side-effects Zolpidem Oral tablet 1.6 ( ) 2.5 ( ) 5 10 Yes Most widely-prescribed hypnotic Zolpidem: Extended Release (Ambien CR ) 1.5 ( ) 2.8 ( ) Yes Higher concentrations 3-8 hours post dose than traditional zolpidem Zolpidem: Sublingual (Intermezzo ) 0.6 ( ) 2.5 ( ) Yes Buffer permits increased buccal absorp, lower dose Zolpidem: Sublingual (Edluar ) 1.4 ( ) 2.7 ( ) 10 Yes Mainly absorbed via GI tract Zolpidem: Oral Spray (Zolpimist ) ( ) 10 Yes Bioequivalent to tablets in terms of C max, T max, t 1/2
39 Class/Drug T Max (hours) Sedating antidepressant drugs Half Life (hours) Mechanism 2 Usual Hypnotic Dose (mg) FDA Approved Indication Comments, Side Effects Doxepin 3.5 (1.5 4) 15 (10 30) Low dose: H1 antagonist Higher doses: 5HT 2, α 1, M 1, antagonist; NE, 5HT reuptake inhibitor 3 6 (Silenor ) (generic) Insomnia Depression Anxiety 3-6 mg dose approved for insomnia; Side effects at higher doses: orthostatic hypotension, anticholinergic, cardiac conduction delay Amitriptyline (5 45) 5HT 2, α 1, M 1 antagonist; NE, 5HT reuptake inhibitor Depression Side effects at higher doses: orthostatic hypotension, anticholinergic, cardiac conduction delay Trazodone (7 15) 5HT 2, α 1, H 1 antagonist; 5HT reuptake inhibitor Depression Side effects: dizziness, risk of priapism Mirtazapine 2 (1 3) 30 (20 40) Edited from Table 4 in Buysse DJ JAMA HT 2-3, α 1-2, H 1, M 1 antagonist; 5HT reuptake inhibitor Depression Increased appetite, weight gain, anticholinergic
40 Slide borrowed from Suzie Bertisch,
41 Slide borrowed from Suzie Bertisch, MD Buscemi N, et al JGIM Sep 22(9):133-50
42 Edited from Table 4 in Buysse DJ JAMA 2013 Class/Drug T Max (hours) Half Life (hours) Mechanism 2 Usual Hypnotic Dose (mg) FDA Approved Indication Comments, Side Effects Melatonin agonist drugs Melatonin MT 1, MT 2 agonist No FDA approval FDA defined as a dietary supplement Ramelteon 0.75 ( ) MT 1, MT 2 agonist 8 Insomnia Main effect on sleep latency Anticonvulsant drugs Gabapentin Uncertain. GABA analog, but does not have activity at GABA receptors. Possible alpha 2 - delta receptor ligand Post herpetic neuralgia; epilepsy Renal excretion,non-linear pharmacokinetics (reduced bioavailability at higher doses); dizziness, ataxia, fatigue Pregabalin alpha 2 -delta receptor ligand. GABA analog, but does not have activity at GABA receptors Diabetic peripheral neuropathy; Post herpetic neuralgia; Adjunct for partial seizures; Fibromyalgia Renal excretion; dizziness, headache, weight gain, dry mouth
43 Edited from Table 4 in Buysse DJ JAMA 2013 Class/Drug T Max (hours) Half Life (hours) Mechanism 2 Usual Hypnotic Dose (mg) FDA Approved Indication Comments, Side Effects Sedating antipsychotic drugs Olanzapine HT 2, D 1-4, α 1, H 1, M 1-5 antagonist Schizophrenia Bipolar Disorder Hypotension weight gain, akathisia, dizziness Quetiapine HT 1-2, D 1-2, α 1-2, H 1 antagonist Schizophrenia Bipolar Disorder Dry mouth, constipation, weight gain, asthenia, headache Antihistamine drugs Diphenhydramine H 1, M 1 antagonist Allergic reactions, motion sickness, Parkinsonism Anticholinergic Doxylamine H 1, M 1 antagonist 25 mg Allergies, hypersensitivity, insomnia Anticholinergic; Dystonic reaction
44 Clonidine Used frequently in children with insomnia and ADHD or ASD 1 Prazosin Effective for treatment of nightmares in patients with PTSD 2 Gabapentin Some efficacy in treatment of hot flashes 3 1 Barrett JR Journal Child Adolescent Psychopharm 2013, 2 Hudson SM Prim Care Companion CNS Disord Saadait N Glob J Health Sci 2013
45 Orexin antagonist, recently FDA approved Suvorexant blocks OX1 and OX2 receptors Orexins promote wake and suppress REM sleep Orexin neurons are absent in narcoleptics with cataplexy
46 LPS WASO Dosing: non-elderly 20 or 40 mg elderly15 or 30 mg. n>250 in each group. Herring, et al, 2014
47 Efficacy Results from Herring et al. Kunal V. Ann Pharmacother 2015
48 Adverse Drug Events Associated With Suvorexant Kunal V. Ann Pharmacother 2015
49 Start at 10 mg qhs, increase to 20 mg if needed Concerns: Safety & efficacy similar in elderly, but consider lower dose Metabolized by CYP3A; do not use in pt with hepatic failure May cause hypnagogic hallucinations or sleep paralysis Do not use in pt with narcolepsy May worsen depression No obvious worsening of OSA or COPD Abuse & dependence: Among polydrug users, drug liking similar to zolpidem (both at high doses) No evidence of physical dependence Doses up to 240 mg cause just sleepiness
50 DBPCT found that eszopiclone 3mg improved sleep quality and duration without prolonging resp events or worsening hypoxemia 1 RCT showed eszopiclone group had greater CPAP adherence (1.3hr more of CPAP use per night). Another study showed use of eszopiclone during CPAP titration improved short term CPAP adherence. 2,3,4 Trazodone at doses up to 100mg increases arousal threshold in response to hypercapnia and allows patients to tolerate higher CO2 levels 5 RDBPCT showed shorter SOL with ramelteon in older individuals starting on APAP therapy without affecting APAP adherence or daytime function 6 1 Eckert DJ Clin Sci 2011, 2 Lettieri CJ Ann Intern Med 2009, 3 Bradshaw DA Chest 2006, 4 Lettieri CH Chest 2009, 5 Heinzer RC Eur Respir J 2008, 6 Gooneratne NS J Clin
51 Insomnia is one of the diagnostic features of depression. Data suggests that insomnia often predates depression. Insomnia is a risk factor for depression, anxiety, substance abuse and suicide 1 In study of adolescents, 69% of insomnia cases preceded comorbid depression and anxiety disorder preceded insomnia 73% of the time 2,3 Longterm outcomes sig improve when insomnia is managed concurrently 4 Adding trazodone (50-100mg) to SSRI has been shown to improve insomnia with comorbid depression 5 Eszopiclone and fluoxetine assoc with greater sleep improvements and depression scores than SSRI alone 6 1 Taylor DJ Behav Sleep Med 2003, 2 Mindell JA Pediatrics 2006, 3 Johnson EO Pediatrics 2006, 4 Riemann D Drugs 2009, 5 Nierenberg AA Am J Psychiatry 1994, 6 Fava M Biol
52 Discussed how her hypervigilance affects her sleep and makes it hard for her to relax Discussed how her childhood history and work stress have contributed to her hypervigilance Had her d/c sonata and lunesta 1mg Wrote her for lunesta 3mg qhs Sleep restriction: Instructed her to take at 1am and get into bed at 2am and to rise by 7am One week later we added clonidine 0.1mg Instructed to continue with regular PAP therapy
53 3 weeks later Ms G returned for followup: Sleeping much better with lunesta 3mg and clonidine 0.1mg Found comfort and reassurance in the acknowledgment of her hypervigilance, of the safety she finds with sleeping with her 4 dogs and for permission to go to bed later Felt more relaxed and accepting of her situation Got a book light to use with reading prior to bed and now gets sleepy after about 45 min Feels more refreshed during the day
54 Thank you!
Insomnia: Updates in Medical Management. Michael Newnam M.D.
Insomnia: Updates in Medical Management Michael Newnam M.D. Sleep Neurobiology Delicate balance of excitatory and inhibitory neurotransmitters that control the switch between wakefulness and sleep Circadian
More informationHow to Manage Insomnia with and without medications
How to Manage Insomnia with and without medications Tatyana Gurvich, Pharm.D. USC School of Pharmacy UC Irvine SeniorHealth Center Insomnia: How common is it? 26-50% of adult population complain of insomnia
More informationManaging Insomnia Disorder A Review of the Research for Adults
Managing Insomnia Disorder A Review of the Research for Adults e Is This Information Right for Me? This information is right for you if: Your health care professional said you have insomnia disorder (said
More informationCPT David Shaha, MC US Army
CPT David Shaha, MC US Army None Thoughts and comments are my own and do not represent the official policy of the Department of the Army, Department of Defense, or United States Government. Clinical Case
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Anxiolytic and Hypnotic Drugs Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 OTHER ANXIOLYTIC AGENTS/ A. Antidepressants Many antidepressants are effective in the treatment
More informationInsomnia treatment in primary care
Insomnia treatment in primary care Daniel J. Buysse, MD UPMC Professor of Sleep Medicine Professor of Psychiatry and Clinical and Translational Science University of Pittsburgh School of Medicine buyssedj@upmc.edu
More informationInsomnia. Arturo Meade MD
Insomnia Arturo Meade MD Goals Definition Prevalence Pathophysiology The role of Orexin Orexin receptor blockers Consequences: Daily Functioning Insomnia: Consequences Decreased quality of life
More informationDr Alex Bartle. Sleep Well Clinic
Dr Alex Bartle Sleep Well Clinic Overview of Sleep Disorders Sleep: Why bother. Effect of Poor Quality or reduced Quantity of Sleep Common Sleep Disorders Management of Insomnia Medication vs CBTi Conclusion
More informationSleep Disorders: Assessment and Therapeutic Options
Sleep Disorders: Assessment and Therapeutic Options John W. Winkelman MD, PhD Chief, Sleep Disorders Clinical Research Program Departments of Psychiatry and Neurology Massachusetts General Hospital Professor
More informationInsomnia. Learning Objectives. Disclosure 6/7/11. Research funding: NIH, Respironics, Embla Consulting: Elsevier
Insomnia Teofilo Lee-Chiong MD Professor of Medicine National Jewish Health University of Colorado Denver School of Medicine Learning Objectives Learn about the causes of transient and chronic Learn how
More informationInsomnia treatment. Sleep hygiene education sleep hygiene teaches good sleeping habits. This includes:
Insomnia treatment INSOMNIA OVERVIEW insomnia is defined as difficulty falling asleep, difficulty staying asleep, or waking up early in the morning and not being able to return to sleep. In general, people
More informationThe Medical Letter. on Drugs and Therapeutics. Usual Adult Hypnotic Dose 1,2 Some Adverse Effects Comments Cost 3
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationPharmacological Help for a Good Night s s Sleep. Thomas Owens, MD
Pharmacological Help for a Good Night s s Sleep Thomas Owens, MD Objectives 1. Define insomnia and characterize the symptoms and array of causes. 2. Describe traditional and new pharmacologic approaches
More informationPsychopharmacology of Sleep Disorders
Psychopharmacology of Sleep Disorders John W. Winkelman MD, PhD Chief, Sleep Disorders Clinical Research Program Departments of Psychiatry and Neurology Massachusetts General Hospital Professor of Psychiatry
More information14. Percent Mellinger GD et al. Arch Gen Psychiatry. 1985;42: ICSD III
4:45 5:45 pm Management of Insomnia and Other Disorders Presenter Disclosure Information The following relationships exist related to this presentation: Alon Y. Avidan, MD, MPH, FAAN, FAASM: Speakers Bureau
More informationAddressing Pharmacologic Issues in. DSM-5 Sleep-Wake. Insomnia. Disorders. DSM-5 Insomnia Disorder. Insomnia. Disorder
Addressing Pharmacologic Issues in David N. Neubauer, MD Associate Professor of Psychiatry and Behavioral Sciences Johns Hopkins School of Medicine Baltimore, Maryland Restless Legs Syndrome Substance/
More informationAvailable Strengths Limits. 200 mg tablets PA. 50 mg, 150 mg, 200 mg, 250 mg tablets. 500 mg/ml solution PA
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Sleeping Disorders P&T DATE: 12/14/2016 THERAPEUTIC CLASS Psychiatric Disorders REVIEW HISTORY: 2/16, 5/15, 2/12 LOB AFFECTED
More informationModern Management of Sleep Disorders
Modern Management of Sleep Disorders Douglas C. Bauer, MD University of California, San Francisco No Disclosures Case 68 yr. old WF with >15 yr. of poor sleep Difficulty with both initiation and maintenance
More informationQuestion #1. Disclosures. CAPA 2015 Annual Conference. All of the following occur as we get older EXCEPT: Evaluating Patients with Insomnia
Evaluating Patients with Roger D. Seheult, M.D. Pulmonary Critical Care Physician - Beaver Medical Group, Redlands California Assistant Clinical Professor of Medicine - Loma Linda University School of
More informationA Review of Sleep Disorders in Cancer Patients: Finding the Dream Treatment
A Review of Sleep Disorders in Cancer Patients: Finding the Dream Treatment Jordan Pleskow, PharmD Roswell Park Cancer Institute Oncology Symposium 11/11/17 Objectives Evaluate the issues with sleep in
More informationSleep Science: better sleep for you and your patients CHUNBAI ZHANG, MD MPH UW MEDICINE VALLEY MEDICAL CENTER
Sleep Science: better sleep for you and your patients CHUNBAI ZHANG, MD MPH UW MEDICINE VALLEY MEDICAL CENTER Disclosure: Financial - none Non-Financial - none Selected Topics Sleep epidemiology Sleep
More informationTOP 10 LIST OF SLEEP QUESTIONS. Kenneth C. Sassower, MD Sleep Disorders Unit Massachusetts General Hospital for Children
TOP 10 LIST OF SLEEP QUESTIONS Kenneth C. Sassower, MD Sleep Disorders Unit Massachusetts General Hospital for Children QUESTION #1: ARE SLEEP ISSUES IN CHILDREN THE SAME AS IN ADULTS? Distinctive Features
More informationModern Management of Sleep Disorders. If Only I Could Sleep Like I Did Before
Modern Management of Sleep Disorders Douglas C. Bauer, MD University of California, San Francisco No Disclosures If Only I Could Sleep Like I Did Before Sleep Case 52 yr. old WF with >4 yr. of poor sleep
More informationAnxiolytic and Hypnotic drugs
Anxiolytic and Hypnotic drugs Anxiolytic and Hypnotic drugs Anxiety is unpleasant state of tension and fear that seems to arise from unknown source. The symptoms of severe anxiety are similar to those
More informationSLEEP DISORDERS. Kenneth C. Sassower, MD Division of Sleep Medicine; Department of Neurology Massachusetts General Hospital for Children
SLEEP DISORDERS Kenneth C. Sassower, MD Division of Sleep Medicine; Department of Neurology Massachusetts General Hospital for Children Distinctive Features of Pediatric Sleep Daytime sleepiness uncommon
More informationINSOMNIA IN THE GERIATRIC POPULATION. Shannon Bush, MS4
INSOMNIA IN THE GERIATRIC POPULATION Shannon Bush, MS4 CHANGES IN SLEEP ARCHITECTURE 2 Reduction in slow wave sleep (stage 3 and 4) Increase in lighter stages of sleep (stage 1 and 2) Decrease in REM sleep
More informationWhat is sleep? o Sleep is a body s rest cycle.
What is sleep? o Sleep is a state when our senses and motor actvity are relatively suspended; there is a total or partial unconsciousness and all voluntary muscles are inactive. o Sleep is a body s rest
More informationLearning Objectives. Management of Insomnia. Impact of Chronic Insomnia. Insomnia: Definitions. Measurement of Goals. Goals of Therapy 9/29/2017
Learning Objectives Characterize insomnia and its negative effects Management of Insomnia Discuss the goals of treatment Summarize guidelines of management of insomnia including non-pharmacologic and pharmacologic
More information14. Percent
4:30 5:45 pm Management of Insomnia and Other Disorders Presenter Disclosure Information The following relationships exist related to this presentation: Alon Y. Avidan, MD, MPH, FAAN, FAASM: Speakers Bureau
More informationInsomnia Disorder A Journey to the Land of No Nod
Insomnia Disorder A Journey to the Land of No Nod JACQUELINE D. KLOSS, PH.D. P S Y C H O L O G I S T B R Y N M A W R P S Y C H O L O G I C A L A S S O C I A T E S B E H A V I O R A L S L E E P M E D I
More informationSLEEP-WAKE DISORDERS: INSOMNIA. Prof. Paz Gía-Portilla
SLEEP-WAKE DISORDERS: INSOMNIA Prof. Paz Gía-Portilla SLEEP-WAKE DISORDERS AND ICD-10 Chapter V: Mental and Behavioural Disorders F51. Non-organic sleep disorders Chapter VI: Nervous System Illnesses G47.
More informationInsomnia Agents (Sherwood Employer Group)
Insomnia Agents (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf Link to
More informationcontinuing education for pharmacists
continuing education for pharmacists General Insomnia Disorder in Adults and Treatment Guidelines Amanda R. Kriesen, R.Ph., PharmD Volume XXXV, No. 9 Dr. Amanda Kriesen has no relevant financial relationships
More informationTRAZODONE IN INSOMNIA COMORBID WITH DEPRESSION: AN AWAKENING LACK OF STRONG EVIDENCE
TRAZODONE IN INSOMNIA COMORBID WITH DEPRESSION: AN AWAKENING LACK OF STRONG EVIDENCE Gordon Ang, PharmD Central Texas Veterans Health Care System 1/5/2018 1 Abbreviations Abbreviation GERD MDD PTSD PSQI
More informationInsomnia % of adults suffer from chronic and severe insomnia (Complaints of insomnia with daytime consequences)
10-15% of adults suffer from chronic and severe insomnia (Complaints of insomnia with daytime consequences) 30 40% of adults complain of insomnia symptoms only 95% experience insomnia at some time in their
More informationSleep Disorders in the Psychiatric Context
Sleep Disorders in the Psychiatric Context John W. Winkelman MD, PhD Chief, Sleep Disorders Clinical Research Program Departments of Psychiatry and Neurology Massachusetts General Hospital Associate Professor
More informationAnxiety Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Anxiety Pharmacology UNIVERSITY OF HAWAI I HILO PRE NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the normal processing of fear vs fear processing
More informationInsomnia. Dr Terri Henderson MBChB FCPsych
Insomnia Dr Terri Henderson MBChB FCPsych Plan Basics of insomnia Pharmacology Medication CBT Details of insomnia Unsatisfactory sleep that impairs daytime well-being Starts with specific problem or change
More informationRuby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018
Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018 Objectives Describe pharmacology of commonly prescribed drugs for stimulants and hypnotics Brief review of common drugs that affect sleep
More informationModern Management of Sleep Disorders. Case. Introduction. Topics Covered. Douglas C. Bauer, MD University of California, San Francisco
Modern Management of Sleep Disorders Douglas C. Bauer, MD University of California, San Francisco No Disclosures Case 68 yr. old WF with >15 yr. of poor sleep Difficulty with both initiation and maintenance
More informationSleep and Parkinson's Disease
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationTreating sleep disorders
Treating sleep disorders Sue Wilson Centre for Neuropsychopharmacology Imperial College London sue.wilson@imperial.ac.uk Suggested algorithm for treatment of insomnia Diagnosis of insomnia Associated with
More informationComparison of Insomnia Treatments
PL Detail-Document #280504 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER May 2012 Comparison of Insomnia
More informationEarl J. Soileau, MD, FSAHM Asst Professor, Family Medicine LSU HSC Medical School New Orleans at Lake Charles
Earl J. Soileau, MD, FSAHM Asst Professor, Family Medicine LSU HSC Medical School New Orleans at Lake Charles Sleep Disorders Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD) Sleep
More informationChronic Insomnia: DSM - V. Insomnia DSM - V. Patient Symptoms. Insomnia: Assessment and Overview of Management. Insomnia Management in the Digital Age
Insomnia Management in the Digital Age Dr Anup Desai Sleep & Respiratory Medicine MBBS (syd), PhD (syd), FRACP Senior Staff Specialist, POW Hospital Medical Director, Sydney Sleep Centre Senior Lecturer,
More informationInsomnia CLINICAL CROSSROADS CLINICIAN S CORNER
CONFERENCES WITH PATIENTS AND DOCTORS CLINICIAN S CORNER Insomnia Daniel J. Buysse, MD, Discussant DR SHIP: Ms J is a 51-year-old woman with insomnia, which began at age 35 years when her infant daughter
More informationMichelle Zetoony, DO, FCCP, FACOI th Avenue S, Suite A Phone: Fax:
Michelle Zetoony, DO, FCCP, FACOI 545 4 th Avenue S, Suite A Phone: 727-826-0933 Fax: 727-826-0744 http://www.dosleep.com SLEEP TALK 9/9 BMJ Open2012 Pharmacology and therapeutics Research What is sleep?
More informationInsomnia. St. Joseph s Annual Family Practice Refresher March 1, Robert J. Ostrander, M.D
St. Joseph s Annual Family Practice Refresher March 1, 2018 Robert J. Ostrander, M.D If in bed I say, When shall I arise? then the night drags on; I am filled with restlessness until the dawn. Job 7:4
More informationAn algorithm for medication in the treatment of Complex PTSD
An algorithm for medication in the treatment of Complex PTSD Andreas Laddis, M.D. aladdis@gmail.com ESTD Conference Bern November 10, 2017 The purpose for the presentation Algorithm for medication: My
More informationCBT for Insomnia: Past, Present, and Future Directions
CBT for Insomnia: Past, Present, and Future Directions J. Todd Arnedt, Ph.D. Associate Professor of Psychiatry and Neurology Director, Behavioral Sleep Medicine Program Acting Director, Sleep and Circadian
More informationWHEN SHOULD I USE SLEEP AIDS IN MY PATIENTS WITH SLEEP DISORDERS... (AND WHEN SHOULD I NOT?)
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences WHEN SHOULD I USE SLEEP AIDS IN MY PATIENTS WITH SLEEP DISORDERS... (AND WHEN SHOULD I NOT?) CATHERINE MCCALL, MD
More information3/24/2016 DISCLOSURE STATEMENT PHARMACIST OBJECTIVES OVERVIEW TECHNICIAN OBJECTIVES PREVALENCE OF INSOMNIA THE WRONG SIDE OF THE BED: CHRONIC INSOMNIA
DISCLOSURE STATEMENT I do not have any actual or potential conflict of interest in relation to this presentation THE WRONG SIDE OF THE BED: CHRONIC INSOMNIA DANIELLE ROWAN, PHARMD, MBA PGY1 PHARMACY PRACTICE
More informationAnxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anxiolytic, Sedative and Hypnotic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anxiolytics: reduce anxiety Sedatives: decrease activity, calming
More informationINSOMNIA IN GERIATRICS. Presented By: Sara Kamalfar MD, Geriatrics Medicine Fellow
INSOMNIA IN GERIATRICS Presented By: Sara Kamalfar MD, Geriatrics Medicine Fellow Insomnia Insomnia is the inability to fall asleep, the inability to stay asleep, or waking up earlier than desired. To
More informationSleeping Pills and Natural Sleep Aids
Sleeping Pills and Natural Sleep Aids Prescription and Over-the-Counter Products It s the middle of the night, and you re staring at the ceiling, thinking about work, or bills, or the kids. Sleep just
More information일차진료에서불면증치료 김종우. Primary Insomnia : DSM-IV criteria 경희대학교의과대학정신과학교실 MEMO. Diagnostic Criteria for Insomnia (ICSD-2) 개원의와함께하는임상강좌
개원의와함께하는임상강좌 2011 일차진료에서불면증치료 경희대학교의과대학정신과학교실 김종우 Diagnostic Criteria for Insomnia (ICSD-2) International Classification of Sleep Disorders, 2nd Edition (ICSD-2) Primary Insomnia : DSM-IV criteria A. The
More informationDSM-5 INSOMNIA. Maintaining. Maintaining Sleep. Difficulty Falling Asleep: Difficulty. Early AM awakenings: (> 30 minutes before desired wake time)
DSM-5 INSOMNIA 3 nights/wk 3 months Difficulty Falling Asleep: > 30 minutes Difficulty Maintaining Sleep Next Day Consequences Early AM awakenings: (> 30 minutes before desired wake time) Initiation Trouble
More informationSleep Disorders and Insomnia
7:45 8:45 am Management of Insomnia and Other Disorders SPEAKER Alon Y. Avidan, MD, MPH, FAAN, FAASM Presenter Disclosure Information The following relationships exist related to this presentation: Alon
More informationDrugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD
Drugs, Sleep & Wakefulness Brian Koo Reena Mehra MD MS Kingman Strohl MD Things To Keep In Mind Many drugs effect sleep either causing insomnia or sedation Disruption of sleep and wakefulness may not be
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationParkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute
Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute Parkinson s Disease 2 nd most common neurodegenerative disorder Peak age at onset is 60 years
More informationDisclosure. Objective 1. Objective 2. Naval Health Center New England. Objective 3. APNA 27th Annual Conference Session 1036: October 9, 2013
Understanding Sleep and Antidepressants: Lessons from Research Literature and Clinical Practice Joseph M. Holshoe, PMHNP-BC Commander, U.S. Public Health Service Behavioral Health Consultant, Primary Care
More informationOBJECTIVES. The psychiatric, medical, and neurologic causes of sleep problems. Office-based and objective methods of evaluating sleep
SLEEP ISSUES 1 OBJECTIVES 2 Know and understand: Age-related changes in sleep The psychiatric, medical, and neurologic causes of sleep problems Office-based and objective methods of evaluating sleep Appropriate
More informationSleep and Insomnia 2/8/2018. Presented by. Marie Rataj, MSN, APRN, ANP. Objectives. Everything you wanted to know
Sleep and Insomnia Everything you wanted to know Presented by Marie Rataj, MSN, APRN, ANP Objectives Develop a basic knowledge of normal sleep and differentiate from abnormal sleep Develop basic understanding
More informationSleep in Children and Teens: Medical Aspects
Sleep in Children and Teens: Medical Aspects Dr. Hazen Gandy, M.D., FRCP (C) Psychiatrist Hub Specialist, Project ECHO Ontario Child and Youth Mental Health Tuesday, November 27, 2018 Faculty and/or presenter
More informationAntidepressants and Sedatives. David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School
Antidepressants and Sedatives David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School Depression A frequent problem, affecting up to 5% of the population Common presentations
More informationPsychobiology Handout
Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are
More informationAGING CHANGES IN SLEEP
OBJECTIVES: Understand the common age-related changes in sleep Discuss the evaluation of the older person with sleep complaints Identify sleep apnea, PLMS, RLS, and REM sleep disorders and their treatments
More informationSedative/Hypnotic Agents. Sedative/Hypnotic Agents. Central Nervous System Depressants. Sedative/Hypnotic Agents(cont d) Sleep
Central Nervous System Depressants Sedative Drugs that have an inhibitory effect on the CNS to the degree that they reduce: Nervousness, excitability, irritability Without causing sleep Hypnotics Calm
More informationWHY CAN T I SLEEP? Deepti Chandran, MD
WHY CAN T I SLEEP? Deepti Chandran, MD Sleep and Aging How does sleep change as we age? Do we need less sleep as we get older? Can a person expect to experience more sleep problems or have a sleep disorder
More informationBenzodiazepines. Benzodiazepines
: History 1950s - Invented by Swiss chemists who identified its sedative effects 1950s 60s - Chlordiazepoxide (Librium) marketed as a safer alternative to barbiturates; along with newer benzodiazepines
More informationAddressing the Multiple Causes and Lifestyle Impacts of Insomnia: A Guide for Patient Counseling
Addressing the Multiple Causes and Lifestyle Impacts of Insomnia: A Guide for Patient Counseling Educational Objectives: At the completion of this knowledge-based activity, participants will be able to:
More informationTreating Insomnia in Primary Care. Judith R. Davidson Ph.D., C. Psych. Kingston Family Health Team
Treating Insomnia in Primary Care Judith R. Davidson Ph.D., C. Psych. Kingston Family Health Team jdavidson@kfhn.net Disclosure statement Nothing to disclose A ruffled mind makes a restless pillow. ~ Charlotte
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Non-Benzodiazepine Insomnia Reference Number: CP.PMA_10.11.23 Effective Date: 07.16 Last Review Date: 04.18 Line of Business: Medicaid- Arizona (AHCS, CIC) Revision Log See Important Reminder
More informationInsomnia. Stages of sleep. Insomnia: Catching Your ZZZs
Insomnia: Catching Your ZZZs Troy Payne MD, FAASM Medical Director, St. Cloud Hospital Sleep Center Diplomate of the American Academy of Psychiatry and Neurology in the Subspecialty of Sleep Medicine Insomnia
More informationInsomnia Treatment in Brief
Insomnia Treatment in Brief Project ECHO May 7, 2015 Jonathan Emens, M.D. Associate Professor, Departments of Psychiatry and Internal Medicine Oregon Health & Science University Staff Physician and Sleep
More information노인병원에서 Light Therapy 의 활용 박 기 형 진주삼성병원 송도병원 신경과
Light Therapy 1 : 15 / 63 (23.8%) 1 : 7 2 : 8 : 6 / 86 (7%) 1, : 48 / 205 (23.4%) 1 : 43 2 : 5 Sleep in Geriatrics Prevalence NIH survey of 9000 american senior above age 65 ; 88% had sleep disturbances
More informationGuideline for Adult Insomnia
Guideline for Adult Insomnia Exclusions This guideline does not apply to: Children under the age of 18 Pregnant and lactating women Geriatric patients: While the general principles of the diagnosis and
More informationSleep Dysfunction in Multiple System Atrophy DR CALLUM DUPRE NEUROLOGY/SLEEP MEDICINE CAPITAL HEALTH SYSTEM
Sleep Dysfunction in Multiple System Atrophy DR CALLUM DUPRE NEUROLOGY/SLEEP MEDICINE CAPITAL HEALTH SYSTEM Categories of Disturbance Sleep Breathing Disorders Parasomnias Sleepiness Insomnia Breathing?
More informationSleep Clinic Case: History. Insomnia in Patients with Comorbid Psychiatric Disorders: Shared Neurobiology and Clinical Solutions
Sleep Clinic Case: History Insomnia in Patients with Comorbid Psychiatric Disorders: Shared Neurobiology and Clinical Solutions David N. Neubauer, MD Associate Professor Johns Hopkins University School
More informationDefinitions. Prevalence. Chronic Insomnia DSM-5 INSOMNIA. Insomnia Is a Distinct Disorder That Should Be Treated ~10% 3 nights/wk 3 months
Chronic Definitions Alon Y. Avidan, M.D., M.P.H UCLA Sleep Disorders Center Is a Distinct Disorder That Should Be Treated NIH (1983) 1 NIH (2005) 2 is a symptom, is a disorder not a disorder DSM-5 INSOMNIA
More informationYour sleep is a reflection of your life
Sleep Disorders and Developmental Disabilities Rafael Pelayo, MD Do you really want to sleep like a baby? He/She won t sleep What goes through your mind when you hear this?? Your life is reflected in your
More informationObjectives. Types of Sleep Problems in Developmental Disorders
Objectives Sleep Problems in the Child with Neurodevelopmental Disorders AACPDM September 11, 2014 BRK-3 Golda Milo-Manson MD, MHSc, FRCP(C) Holland Bloorview Kids Rehabilitation Hospital Toronto, Canada
More informationDrug Review Rozerem (ramelteon)
Drug Review Rozerem (ramelteon) Introduction 1 Ramelteon is a melatonin receptor agonist with affinity for MT 1 and MT 2 and selectivity over the MT 3 receptor. The activity at the MT 1 and MT 2 receptors
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Non-Benzodiazepine Insomnia Medications Reference Number: CP.HNMC.265 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder
More informationCognitive-Behavioral Therapy for Insomnia
Wisconsin Department of Health Services Wisconsin Public Psychiatry Network Teleconference (WPPNT) This teleconference is brought to you by the Wisconsin Department of Health Services (DHS) Bureau of Prevention,
More informationTranquilizers & Sedative-Hypnotics
Tranquilizers & Sedative-Hypnotics 1 Tranquilizer or anxiolytic: Drugs used therapeutically to treat agitation or anxiety Sedative-Hypnotic: drugs used to sedate and aid in sleep Original sedatives (before
More informationFaculty/Presenter Disclosure
A Little CBT I With My Tea Please: Cognitive Behavioural Therapy for insomnia (CBT I) and Its Use In the Treatment of Sleeplessness W. Jerome Alonso, MD Medical Director, Canadian Sleep Consultants Clinical
More information6/3/2015. Insomnia An Integrative Approach. Objectives. Why An Integrative Approach? Integrative Model. Definition. Short-term Insomnia
Insomnia An Integrative Approach Jeffrey S. Jump, M.D. Medical Director CHI Memorial Integrative Medicine Associates Objectives Understand the importance of sleep to health Identify patients with insomnia
More informationDisclosure. Sleep Medications in Primary Care: How to choose, what to avoid
Sleep Medications in Primary Care: How to choose, what to avoid Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP President, Fitzgerald Health Education Associates, North Andover,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Non-Benzodiazepine Insomnia Medications Reference Number: CP.CPA.265 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at
More informationIntroduction. v Insomnia is very prevalent in acute (30-50%) and chronic forms (10-15%). v Insomnia is often ignored as a symptom of other disorders.
Introduction v Insomnia is very prevalent in acute (30-50%) and chronic forms (10-15%). v Insomnia is often ignored as a symptom of other disorders. v Insomnia is a risk factor for psychiatric and medical
More informationInsomnia: habits, help, and hazards
Insomnia: habits, help, and hazards Balanced data about medications www.rxfacts.org Copyright 2010 by The Alosa Foundation www.rxfacts.org November 2010 2 www.rxfacts.org Author: Leslie Jackowski, B.Sc.,
More informationSleep History Questionnaire
Location South Loop Katy Steeplechase Fort Bend NAME ADDRESS PHONE SEX DOB AGE HEIGHT WEIGHT NECK COLLAR SIZE (inches) Do you have difficulty falling asleep? Is your sleep restless or disturbed? Do you
More informationAnxiolytic & Hypnotic Drugs. Asst Prof Dr Inam S Arif
Anxiolytic & Hypnotic Drugs Asst Prof Dr Inam S Arif isamalhaj@yahoo.com Anxiolytic & Hpnotic Agents Anxiety: unpleasant state of tension, apprehension or uneasiness, characterised by, tachycardia, sweating,
More informationANTIANXIETY DRUGS: BENZODIAZEPINES
Margaret Gnegy Professor of Pharmacology pgnegy@umich.edu 1 ANTIANXIETY DRUGS: BENZODIAZEPINES Sedatives and hypnotics M. Gnegy, Ph.D. 1 2 Reading: Goodman & Gilman, 11th ed. Chapter 16, pp. 401-427. Drug
More informationSedatives and Hypnotics. Ahmad Al-Tarifi. Zahra Khalil. Pharmacology. 1 P a g e
Sedatives and Hypnotics Ahmad Al-Tarifi Zahra Khalil 1 P a g e Pharmacology 7 OCD can lead to an anxious behavior and anxiety can be treated with drugs called Sedatives and Hypnotics. What are sedatives?
More informationIndex. sleep.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Actigraphy, 475, 485, 496 Adolescents, sleep disorders in, 576 578 Adults, sleep disorders in, 578 580 Advanced sleep phase disorder, 482 Age,
More informationWELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS
WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS Prior to your office visit, we request that you complete this questionnaire. It asks questions not only about your sleeping habits and behavior
More informationIndex. sleep.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Accidents, risk of, with insufficient sleep, 318 Acquired immunodeficiency syndrome (AIDS), comorbid with narcolepsy, 298 299 Actigraphy, in
More information